TX-PHILLIPS-66
19.7.2022 15:02:13 CEST | Business Wire | Pressemeddelelse
Phillips 66 (NYSE: PSX) og H2 Energy Europe ("H2 Energy") meddelte i dag, at de har indgået en 50-50 joint venture-aftale med henblik på etablering og drift af et netværk af brinttankstationer og skabelsen af et grønt brintøkosystem i Tyskland, Østrig og Danmark.
JET H2 Energy Austria GmbH (JET H2 Energy), som udgør joint venture-aftalen mellem datterselskaberne Phillips 66 Limited og H2 Energy Europe SA, forener Phillips 66's store ekspertise inden for detailhandel med H2 Energys erfaringer og ekspertise inden for brint. JET H2 Energy bliver en central aktør i branchen og vil sætte skub i udviklingen af brint som brændstof i Europa. Det nye selskab planlægger at etablere cirka 250 brinttankstationer inden 2026.
"Det er vores mål at gøre brint til en førende energibærer inden for emissionsfri mobilitet. Vi vil skabe ligevægt i de involverede aktørers interesser i hele brintværdikæden og skabe et bæredygtigt brintøkosystem,” udtaler Olaf Borbor, administrerende direktør for JET H2 Energy.
"Phillips 66 er med stor succes til stede på detailmarkedet i Europa med sit brand JET® . H2 Energy har en dokumenteret track record inden for skabelsen af et vellykket grønt brintøkosystem i Schweiz. Parternes kompetencer supplerer derfor hinanden ideelt i den næste fase i udviklingen af brintøkonomien."
JET H2 Energy vil søge og udvælge steder (greenfield-udvikling, JET® og kundesteder), etablere og drive brinttankstationer til både tunge og lette køretøjer og personbiler (FCEV'er), forsyne brinttankstationerne med grøn brint og opbygge relationer med kunder og originaludstyrsproducenter.
JET H2 Energy vil drage fordel af sit tætte samarbejde med Hyundai Hydrogen Mobility, der er eksklusiv europæisk forhandler af Hyundai Xcient-brintbrændselscellelastbilen.
Ledelsesteamet består af Olaf Borbor (CEO), Markus Wolf (CFO) og Jonas Erdmann (Commercial Manager). Det tyske hovedkvarter er baseret i Hamborg.
Phillips 66 Limited er en kombineret energiproduktions- og logistikvirksomhed hjemhørende i Storbritannien. Virksomheden er et datterselskab under og 100 % ejet af Phillips 66. Phillips 66 har med flere end 1.000 JET® -stationer en stærk tilstedeværelse på markedet i Europa og via joint venture-samarbejdet Coop Mineraloel AG et voksende netværk til optankning af brint i Schweiz.
H2 Energy Europe med hovedsæde i Schweiz er et joint venture mellem selskabet Trafigura Pte Ltd., der handler med råvarer, og H2 Energy Holding AG, en førende brintleverandør i Europa med investeringer i produktion, distribution og anvendelse af grøn brint. H2 Energy var gennem sine tilknyttede selskaber den første til at udvikle og levere brintbrændselscellelastbiler til kommercielle brugere og skabe et grønt brintbrændstof-økosystem i Schweiz.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220718005806/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum